The Research Of The Platform Strategy Of Multinational Pharmaceutical In China In The Smart Medical Care As Company A

The pharmaceutical industry is important to national economy and people’s livelihood which has impacted on the people’s health.Current,the China Pharmaceutical Industry has a great change in drug sales.With the development of emerging technology,smart medical care has a huge impacted on the pharmaceutical industry.Therefore,it is necessary to analyze the enterprises in the pharmaceutical industry to explore its strategic development under the new situation.Before the case analysis,the system analysis method and the literature research method are used to summary the relevant Strategy management theory in this study,and the theoretical basis is laid the theoretical basis for the development of subsequent case studies.During this study,not only analyze the platform strategy of the Company A,but also analyzed the development status of domestic and foreign pharmaceutical industries and emerging technologies such as the Internet for the impact of the pharmaceutical industry which are the key point of the medical enterprises change in China.Foucused on the business and sales problem of multinational pharmaceutical Company A in China,combined with the Internal innoviation center in China.By the PEST and Porter five-power model analysis tools,the internal and external environment has been analyzed to identify the impact of environmental changes on the Company A in China.With SWOT’s analysis tool,the Company A is analyzed in the business of the business in China,and finally derived the strategic direction of the Company A in China to develop through platform-based integrated resources and focusing product advantages.The case analysis method is used to analyze the cases in this paper,identifying the platform strategic point of the Company A and the following control measures to use.The final research results of this study help cards from the platform strategic starting point,advantage,implementation results,and follow-up points of the platform,which can also be borrowed by the domestic pharmaceutical enterprise development strategy.